---

Market Overview

---

The non-invasive liquid biopsy industry is recognized as one of the most rapidly evolving and dynamic markets. It is projected that the global market for non-invasive liquid biopsy will grow at a compound annual growth rate (CAGR) of 20.38% during the forecast period from 2021 to 2031. This growth is driven by several factors, including the global increase in cancer prevalence, the rise in government funding for healthcare, the preference of patients for non-invasive cancer diagnosis, and the growing prominence of precision medicine in the field of oncology.

The market is benefiting from advancements in cancer molecular diagnostic testing, particularly in non-invasive liquid biopsy. Currently, there is a surge in the non-invasive liquid biopsy industry due to the rising number of cancer cases worldwide, increased government funding for healthcare, patient demand for non-invasive diagnostic methods, and the adoption of precision medicine in oncology.

Biotechnology companies are focusing on developing robust non-invasive liquid biopsy solutions for various applications, including oncology, reproductive health, and metabolic disorders. These solutions enable clinicians to analyze genetic alterations present in circulating biomarkers obtained from samples such as stool, urine, and saliva. Non-invasive liquid biopsy products and services facilitate early cancer screening and diagnosis, leading to improved survival rates for patients.

The research report segments the market based on offering, sample type, application, technology, end users, and region. Each segment provides an overview of the market over the projected years, revenue trends, underlying patterns, and emerging trends based on primary and secondary data analysis.

Compared to conventional blood-based liquid biopsies and tissue-based biopsies, non-invasive liquid biopsy is a relatively new field. It utilizes non-invasive samples like stool, urine, and saliva to analyze genetic alterations in circulating biomarkers, enabling early-stage cancer screening and diagnosis. Non-invasive liquid biopsy offers optimal patient comfort and ease of use, making it suitable for routine check-ups. According to the World Health Organization (WHO), cancer is the leading cause of death worldwide, with approximately 10 million deaths in 2020. The increasing healthcare burden caused by the growing number of cancer cases has fueled the development of high-fidelity diagnostic approaches. As cancer treatment relies heavily on advanced screening and diagnosis, the non-invasive liquid biopsy field is expected to experience significant growth in the coming years.

Furthermore, advancements in molecular technologies and a deeper understanding of cancer genomic mechanisms have the potential to revolutionize healthcare and medicine globally. Innovations such as next-generation sequencing (NGS) and polymerase chain reaction (PCR) enable accurate quantification and analysis of circulating biomarkers in non-invasive sample types that are challenging to detect using traditional molecular biology techniques. Consequently, manufacturers and service providers in the non-invasive liquid biopsy industry are investing heavily in research and development (R&D) to expand their portfolios, particularly in clinical oncology. As the next frontier of precision medicine, the global non-invasive liquid biopsy market holds immense potential to revolutionize cancer screening and diagnostics.

---

Market Segmentation

---

The market is segmented based on various factors, including offering, sample, application, technology, end users, and region.

Segmentation by Offering
Products (Kits and Assays)
Services

Segmentation by Sample
Stool
Urine
Saliva
Other Samples

Segmentation by Application
Oncology
Reproductive Health
Metabolic Disorders
Other Applications

Segmentation by Technology
Polymerase Chain Reaction (RT-PCR and dPCR)
Sequencing (NGS and Sanger Sequencing)
Microarray
Other Technologies

Segmentation by End User
Hospitals and Diagnostic Laboratories
Academic and Research Institutions
Other End Users

Segmentation by Region
North America – U.S., and Canada
Europe – Germany, U.K., France, Italy, Spain, the Netherlands, and Rest-of-Europe
Asia-Pacific – China, Japan, India, South Korea, Australia, Singapore, and Rest-of-Asia-Pacific
Latin America – Brazil, Mexico, and Rest-of-Latin America
Rest-of-the-World

In 2020, the services segment held the largest share (84.93%) of the global non-invasive liquid biopsy market. This trend is expected to continue during the forecast period (2021-2031), with the segment projected to hold an 80.02% share in 2031. The dominance of the services segment can be attributed to several factors including the growing prominence of early cancer detection, increasing awareness about non-invasive cancer testing, rising prevalence of cancer, and the adoption of precision medicine strategies. Additionally, the increasing adoption of Exact Sciences’ non-invasive stool-based Cologuard test in the U.S. has contributed significantly to the high share of the non-invasive liquid biopsy services segment.

Stool samples accounted for the majority of the global non-invasive liquid biopsy market (74.31%) in 2020. This trend is expected to continue, with the segment projected to hold a 69.91% share in 2031. The significant market share of stool samples is primarily due to the growing adoption of Exact Science’s Cologuard test in the U.S. for colorectal cancer screening. Factors such as the increasing prevalence of colorectal cancer, rising awareness about early screening, and the adoption of precision medicine also contribute to the high market share of stool samples in the global non-invasive liquid biopsy market.

Oncology dominated the global non-invasive liquid biopsy market (89.03%) in 2020. This trend is expected to persist, with the oncology segment anticipated to hold an 88.13% share in 2031. The high share of the oncology segment is driven by the growing focus on cancer research through government-funded initiatives, increasing cancer prevalence, the adoption of non-invasive liquid biopsy products by end-users, and an emphasis on new product development for cancer screening.

Polymerase chain reaction (PCR) technology accounted for the majority of the global non-invasive liquid biopsy market (85.52%) in 2020. This trend is expected to continue, with the PCR segment projected to hold an 81.97% share in 2031. The prominence of PCR is mainly due to its clinical utility and the increasing adoption of PCR-based non-invasive liquid biopsy products. Exact Sciences Corporation has played a significant role in the segment’s high share by incorporating quantitative allele-specific real-time target and signal (QuARTS), an evolution of PCR technology, into their Cologuard test.

Among all end-users, hospitals and diagnostic laboratories held the largest share (82.68%) of the global non-invasive liquid biopsy market in 2020. This trend is expected to continue, with the segment projected to hold an 80.51% share in 2031. The high share of this segment can be attributed to the growing popularity of non-invasive sampling procedures among patients and increasing awareness about early cancer detection and screening. Additionally, the clinical utility of Exact Sciences’ Cologuard test for colorectal cancer screening has supported the segment’s dominance in the global non-invasive liquid biopsy market.

During the forecast period (2021-2031), the North America region is expected to dominate the global non-invasive liquid biopsy market. This growth is primarily driven by the presence of market leaders such as Exact Sciences Corporation in the U.S. and the significant adoption of high-fidelity cancer diagnostics in clinical oncology. Factors such as increasing investments in product development and rising cancer research activities further contribute to the growth of the North American non-invasive liquid biopsy market.

---

Competitive Landscape

---

Key companies profiled in this report include Bio-Techne Corporation, Endress + Hauser Group, Exact Sciences Corporation, Lonza Group AG, MDxHealth, Merck KGaA, MutantDx, Norgen Biotek Corp, Nucleix Ltd., Oasis Diagnostics Corporation, OraSure Technologies, Inc., PerkinElmer Inc., Predicine, Inc., QIAGEN N.V., Thermo Fisher Scientific Inc., Zymo Research Corporation

---

Key Questions Answered

---

How is the field of oncology, reproductive health, and metabolic disorders being revolutionized by non-invasive liquid biopsy?

What are the major market drivers, challenges, and opportunities in the global market for non-invasive liquid biopsy?

What are the underlying factors contributing to the emerging trends within the global non-invasive liquid biopsy market?

How has the COVID-19 pandemic affected the global ecosystem of non-invasive liquid biopsy?

What key development strategies are major players implementing to maintain competitiveness in the market?

What are the regulatory implications in developed and developing regions regarding the use of non-invasive liquid biopsy?

What potential entry barriers are expected for companies seeking to enter specific regions?

How is each market segment projected to grow during the forecast period of 2021-2031, and what revenue is expected from each segment?

What growth opportunities exist for non-invasive liquid biopsy companies in their respective operational regions?

Who are the leading players with significant offerings in the global non-invasive liquid biopsy market?

Which companies are anticipated to have a highly disruptive impact in the future, and what are the reasons behind this anticipation?